Girl’s undisclosed death in gene-editing trial raises red flags in booming Chinese industry

Key Points:

• Shanghai Jiaotong University School of Medicine is investigating the death of a young girl in a gene-editing clinical trial conducted at its affiliated Xinhua Hospital, raising serious ethical concerns in China's biomedical sector.
• The trial, led by neuroscientist Qiu Zilong, involved an experimental gene-editing therapy for a rare neurodevelopmental disorder, but the girl died shortly after treatment; the hospital’s ethics board linked her death to the therapy, though penalties were minor and not publicly disclosed.
• The case has sparked outrage amid China's rapid biotechnology growth and follows previous high-profile gene-editing controversies, highlighting ongoing regulatory gaps in transparency, safety, and accountability despite recent government efforts to strengthen oversight.
• The clinical trial was approved before complete preclinical data were available, and the related research paper published in Nature did not disclose the human trial or the girl's death, prompting calls for investigation and possible retraction.
• New Chinese regulations introduced in 2025 aim to improve oversight of advanced biomedical trials, but experts warn that balancing innovation and patient safety remains a global challenge, and this incident may lead to further tightening of controls in China’s booming biotech industry.